

MEDICAL POLICY

Medical Policy Title	Artificial Lumbar Intervertebral Disc
Policy Number	7.01.63
Current Effective Date	October 15, 2026
Next Review Date	June 2027

Our medical policies are guides to evaluate technologies or services for medical necessity. Criteria are established through the assessment of evidence based, peer-reviewed scientific literature, and national professional guidelines. Federal and state law(s), regulatory mandates and the member's subscriber contract language are considered first in the determination of a covered service.

(Link to [Product Disclaimer](#))

For lumbar fusion (with or without decompression) following failed lumbar total disc arthroplasty surgery (Refer to policy #7.01.117 Lumbar Fusion).

POLICY STATEMENT(S)

Initial Procedure

- I. Initial primary lumbar total disc arthroplasty is considered **medically appropriate** when **ALL** of the following criteria are met:
 - A. Aged 18 to 60 years;
 - B. Use of a Lumbar disc prosthesis approved by the United States Food and Drug Administration (FDA), for an FDA-approved indication, and in accordance with FDA labeling;
 - C. No planned simultaneous fusion (hybrid surgery) at an adjacent lumbar level;
 - D. The planned implant will be used in the reconstruction of a single-level lumbar disc at only one of the following lumbar levels: L3-4, L4-5, or L5-S1;
 - E. Absence of facet ankylosis or severe facet degeneration at the operative level;
 - F. Plain X-rays and advanced diagnostic imaging studies (i.e., CT, MRI) confirm **ALL** of the following:
 1. Presence of moderate to severe single-level disc degeneration at the operative level (between L3-4, L4-5, L5-S1);
 2. Absence of degenerative disc disease at more than one (1) level (between L3-4, L4-5, L5-S1); **and**
 3. Absence of degenerative disc disease above L3-L4;
 - G. Symptoms concordant with single-level lumbar degenerative disc disease (DDD) include:
 1. Significant level of pain on a daily basis, defined as clinically significant functional impairment (e.g., inability to perform household chores, prolonged standing, etc.);
 - H. Significant functional limitations have resulted in diminished quality of life and impaired, age-appropriate activities of daily living;

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 2 of 10

- I. Structured, physician-supervised, multi-modal, non-operative management of medical care with licensed healthcare professionals, which includes **ALL** of the following:
 - 1. regularly scheduled appointments;
 - 2. follow-up evaluation; **and**
 - 3. less than clinically meaningful improvement with **BOTH** of the following for at least six (6) consecutive months, unless contraindicated:
 - a. prescription-strength analgesics, steroids, gabapentinoids or NSAIDs; **and**
 - b. provider-directed exercise program prescribed by a physical therapist, chiropractic provider, or osteopathic or allopathic physician;
 - J. Absence of unmanaged significant mental and/or behavioral health disorders (e.g., major depressive disorder, chronic pain syndrome, secondary gain, opioid use or alcohol use disorder).
- II. Lumbar total disc arthroplasty is considered **not medically necessary** when performed for **ANY** of the following:
- A. Lumbar partial disc prosthetics;
 - B. As an adjunct to the treatment of primary-central or far-lateral disc herniation.
- III. Lumbar artificial total disc arthroplasty is considered **not medically necessary** for **ANY** of the following contraindications:
- A. Performed for the revision of a failed lumbar artificial total disc arthroplasty;
 - B. Individual with osteopenia or osteoporosis (T-score less than -1.0);
 - C. Imaging evidence of **ANY** of the following:
 - 1. Degenerative or lytic spondylolisthesis more than 3 mm;
 - 2. Lumbar spinal stenosis;
 - 3. Pars interarticularis defect with either spondylolysis or isthmic spondylolisthesis;
 - 4. Lumbar scoliosis of more than 11 degrees of sagittal plane deformity;
 - 5. Spinal fracture;
 - 6. Infection;
 - 7. Presence of tumor or active infection at the site of implantation;
 - 8. Lumbar nerve root compression or bony spinal stenosis;
 - 9. Preoperative remaining disc height of less than 3 mm; or
 - 10. Mid-sagittal stenosis of less than 8 mm by MRI;
 - D. History of ankylosing spondylitis, rheumatoid arthritis, lupus, or other autoimmune disorder;

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 3 of 10

- E. Allergy or sensitivity to implant materials;
- F. Isolated radicular compression syndromes, especially due to lumbar disc herniation;
- G. Involved vertebral endplate is dimensionally smaller than the approximate dimensions of the implant in anterior/posterior width and lateral width;
- H. Clinically compromised vertebral bodies at the affected level due to current or past trauma.

RELATED POLICIES

Corporate Medical Policy

7.01.80 Artificial Cervical Intervertebral Disc

7.01.117 Lumbar Fusion

POLICY GUIDELINE(S)

Urgent/Emergent Conditions

- I. All individuals being evaluated for spine surgery should be screened for the presence of urgent/emergent indications/conditions that warrant definitive surgical treatment imaging findings noted in the applicable procedure section(s) are required.
 - A. The following criteria are **NOT** required for confirmed urgent/emergent conditions:
 - 1. Provider-directed non-surgical management;
 - 2. Proof of smoking cessation;
 - 3. Absence of unmanaged significant mental and/or behavioral health disorders (e.g., major depressive disorders, chronic pain syndrome, secondary pain, opioid and alcohol use disorders);
 - 4. Time frame for repeat procedure.
- II. An urgent/emergent request is based on the 2019 NCQA standards for utilization management and is as follows:
 - A. A request for medical care or services where application of the time frame for making routine or non-life-threatening care determinations:
 - 1. Could seriously jeopardize the life or health of the individual or the individual's ability to regain maximum function, based on a prudent layperson's judgment, or
 - 2. Could seriously jeopardize the life, health, or safety of the individual or others, due to the individual's psychological state, or
 - 3. In the opinion of a practitioner with knowledge of the individual's medical or behavioral condition, would subject the individual to adverse health consequences without the care or treatment that is the subject of the request.
- III. Minimum documentation requirements needed to complete a spinal surgery prior authorization

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 4 of 10

request include **ALL** of the following:

- A. CPT codes, ICD-10 codes, and disc levels or motion segments involved for planned surgery must be provided;
- B. Detailed documentation of the type, duration, and frequency of provider-directed non-surgical treatment (e.g., interventional pain management, physical therapy, chiropractic care, or provider-directed active exercise program, etc.) that includes response to each treatment:
 - 1. Detailed documentation explaining why a sufficient trial of non-surgical treatment was contraindicated (if applicable);
 - 2. Detailed documentation of less than clinically meaningful improvement for each treatment;
- C. Written reports/interpretations of the most recent advanced diagnostic imaging reports (e.g., computed tomography [CT] scan, magnetic resonance imaging [MRI], or Myelography) performed, read, and interpreted by an independent radiologist. Clinically significant discrepancies in interpretation between the surgeon and the radiologist need to be reconciled prior to the documentation submission;
- D. The documentation for spinal fusion surgery requests must include flexion-extension plain x-rays based upon indications for instability and/or other plain x-rays that document failure of instrumentation, fusion, etc.

DESCRIPTION

Replacement of the intervertebral disc or the disc nucleus with an artificial device is proposed as an alternative to interbody fusion to treat symptomatic DDD. Interbody fusion, with or without posterior instrumentation, has been the most common surgical treatment for anterior column instability caused by DDD. The procedure is believed to do well in stabilizing the anterior column and relieving pain by eliminating motion. However, it is not physiologic, and it alters the stress distribution on the adjacent segments. The issue of whether this stress alteration leads to symptomatic degeneration is still debated. It is proposed that a more functional device, an artificial disc, would restore not only the anatomy but also normal mechanical function. Many designs have been proposed over the past 40 years, both total disc and disc nucleus (partial disc replacement or PDA) devices.

Total Artificial Disc

A total artificial disc replaces the entire disc, including nucleus, annulus, and end plate, and consists of a polyurethane nucleus designed to fit between two titanium alloy surfaces.

Artificial Disc Nucleus

An artificial disc nucleus is designed to replace only the degenerative nucleus; most of the annulus is left intact. This device consists of a hydrogel core that can absorb fluid and expand when implanted. Partial disc replacement is also referred to as a nucleus arthroplasty.

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 5 of 10

Meyerding Classification Grade of Spondylolisthesis

Meyerding classification is determined by measuring the degree of slip using standing, neutral lateral radiographs of the lumbar spine. The classification system divides slip into five (5) grades:

- Grade I- 0% to 25%
- Grade II- 25% to 50%
- Grade III- 50% to 75%
- Grade IV- 75% to 100%
- Grade V- greater than 100%

SUPPORTIVE LITERATURE

The original FDA approval of the ProDisc-L was based on a randomized, controlled trial (RCT) with 24-month follow-up, comparing disc replacement with spinal fusion. Both treatment groups improved on all outcome measures; by study definitions of improvement on Oswestry Disability Index (ODI) and range of motion, 64% of ProDisc subjects and 45% of the fusion group achieved overall success (53% and 41%, respectively, by the FDA's definitions). J.E. Zigler et al (2012) reported five-year follow-up data of this pivotal trial. Out of an original 236 patients randomized, 186 (79%) were included in the follow-up of clinical outcomes (134 ProDisc and 52 controls) and 166 (70%) were included for radiographic outcomes (123 ProDisc and 43 controls). Results showed non-inferiority but not superiority of artificial disc replacement, with 53.7% of the ProDisc patients and 50% of the fusion patients achieving overall success at five years.

Yue et al. (2019) completed a five-year, non-inferiority trial that compared activL with control total disc replacement systems (TDR), Pro-Disc-L or Charité, in the treatment of patients with symptomatic, single-level lumbar DDD. Originally, 324 patients were randomly allocated (2:1) to treatment with activL (n=218) or control TDR (n=106). At five-year follow-up, 261 patients (176 activL and 85 control) were available for analysis (76.5%). The primary composite endpoint demonstrated non-inferiority at five years for activL, compared to control TDR. Reductions in back pain severity and improvements in ODI were maintained for both the activL and Control TDR groups through five years. Freedom from a serious adverse event through five years was 64% in activL patients, 47% in control patients. The authors concluded that the activL artificial disc is safe and effective for the treatment of symptomatic lumbar DDD through five years. This trial's exclusion criteria (NCT00589797) included pre-operative remaining disc height less than 3mm, mid-sagittal stenosis of less than 8mm (by MRI), degenerative or lytic spondylolisthesis greater than 3mm, lumbar scoliosis (greater than 11 degrees of sagittal plane deformity), facet ankylosis or severe facet degeneration, history of rheumatoid arthritis, lupus, or other autoimmune disorder, and ankylosing spondylitis (Yue and Mo, 2010).

PROFESSIONAL GUIDELINE(S)

North American Spine Society (NASS) 2019 (2024 revision) Coverage Policy for Lumbar Artificial Disc Replacement

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 6 of 10

Indications for lumbar artificial disc replacement include the following:

- Pain arising from 1- or 2 level disc disruption involving L3-4, L4-5, and/or L5-S1 segments.
- Presence of symptoms for at least 6 months or greater, that are not responsive to multimodal nonoperative treatment over that period, which should include a physical therapy/rehabilitation program, and may also include (but not limited to) pain management, injections, cognitive behavior therapy, and active exercise program.
- Primary complaint of axial pain, with a possible secondary complaint of lower extremity pain.

Contraindications to lumbar disc arthroplasty include the following:

- Degenerative disc disease at more than 2 levels;
- Significant facet arthropathy at the index level or signs that the source of pain is primarily facet mediated.
- Spinal instability/spondylolisthesis greater than Grade I;
- Chronic radiculopathy;
- Osteopenia shown on DEXA with a bone mineral density T-score less than or equal to -1.0;
- Poorly managed psychiatric disorder;
- Significant facet arthropathy at the same level;
- Age < 18 yrs. or > 60 yrs.;
- Presence of infection or tumor.

REGULATORY STATUS

The U.S. Food and Drug Administration (FDA) regulates lumbar artificial discs as medical devices. All lumbar artificial discs including related components require FDA approval before marketing and use in the United States to ensure they are safe and effective for human use. Refer to the FDA Medical Device website. Available from: <https://www.fda.gov/medical-devices> [accessed 2026 May 18]

The FDA lists the most serious type of medical device recalls as well as early alert communications about corrective actions being taken by companies that the FDA believes are likely to be the most serious type of recalls. Available from: [Medical Device Recalls](#) [accessed 2026 May 18]

The FDA granted marketing approval for ProDisc in August 2006. The device indications were expanded to include spinal arthroplasty in skeletally mature patients with DDD at one or two intervertebral levels from L3-S1. Patients should have no more than grade 1 spondylolisthesis at the involved level(s) and should have failed at least six months of conservative treatment prior to implantation.

The FDA granted PMA for activL in 2015. While a number of artificial intervertebral discs have been used internationally in the lumbar spine, only three devices (activL, Charité, ProDisc-L) have been approved by the FDA through the pre-market approval (PMA) process. Because the long-term safety and effectiveness of these devices were not known, approval was contingent on completion of post-

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 7 of 10

marketing studies. The activL (Aesculap Implant Systems), Charité (DePuy), and ProDisc-L (Synthes Spine) devices are indicated for spinal arthroplasty in skeletally mature patients with DDD at one level; activL and Charité are approved for use in levels L4-S1; and ProDisc-L is approved for use in levels L3-S1.

The INMOTION lumbar artificial disc (DePuy Spine) is a modification of the Charité device, with a change in name under the same PMA. Production under the name Charité was discontinued in 2010. The INMOTION is not currently marketed in the United States.

Another device, called the Maverick artificial disc (Medtronic), is not marketed in the United States due to patent infringement litigation.

CODE(S)

- Codes may not be covered under all circumstances.
- Code list may not be all inclusive (AMA and CMS code updates may occur more frequently than policy updates).
- (E/I)=Experimental/Investigational
- (NMN)=Not medically necessary/appropriate

CPT Codes

Code	Description
22857	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), single interspace, lumbar
22860	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); second interspace, lumbar (List separately in addition to code for primary procedure)
22862 (NMN)	Revision including replacement of total disc arthroplasty (artificial disc) anterior approach, single interspace, lumbar
22865	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace, lumbar
0164T	Removal of total disc lumbar arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)
0165T (NMN)	Revision including replacement of total disc lumbar arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)
0719T	Posterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment

Copyright © 2026 American Medical Association, Chicago, IL

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 8 of 10

HCP Codes

Code	Description
Not Applicable	

ICD10 Codes

Code	Description
Multiple Codes	

REFERENCES

Bai DY, et al. Total disc replacement versus fusion for lumbar degenerative diseases - a meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. 2019 Jul;98(29):e16460.

Bryant JP, et al. Long-term clinical outcomes with the activ-L lumbar arthroplasty system. *Int J Spine Surg*. 2020 Oct;14(5):731-735.

Delamarter R, et al. Prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement compared with circumferential arthrodesis for the treatment of two-level lumbar degenerative disc disease: results at twenty-four months. *J Bone Joint Surg Am*. 2011 Apr 20;93(8):705-15.

Hayden J, et al. Exercise treatment effect modifiers in persistent low back pain: an individual participant data meta-analysis of 3514 participants from 27 randomised controlled trials. *British Journal of Sports Medicine*. 2019;54:1277-1278.

Jackson KL, et al. Correlating psychological comorbidities and outcomes after spine surgery. *Global Spine J*. 2020;10(7):929-939.

Koutsogiannis P, et al. A cross-sectional analysis of 284 complications for lumbar disc replacements from medical device reports maintained by the United States Food and Drug Administration. *Spine J*. 2022 Feb;22(2):278-285.

Lang SAJ, et al. Advanced meta-analyses comparing the three surgical techniques total disc replacement, anterior stand-alone fusion and circumferential fusion regarding pain, function and complications up to 3 years to treat lumbar degenerative disc disease. *Eur Spine J*. 2021;30(12):3688-3701.

National Institute for Health and Clinical Excellence (NICE) [Internet]. Prosthetic intervertebral disc replacement in the lumbar spine (IPG306). Issue date Jul 2009 [accessed 26 Apr 29]. Available from: <https://www.nice.org.uk/guidance/ipg306>

North American Spine Society (NASS) [Internet]. Coverage policy recommendations. Lumbar artificial disc replacement. 2019 Feb [revised 2024 Aug; accessed 2026 Apr 29]. Available from:

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 9 of 10

<https://www.spine.org/coverage>

Orosz LD, et al. Preserving spinal motion: lumbar disc arthroplasty in the US. Curr Orthop Pract. 2026 Feb 20;37(2):e1349.

Rasouli A, et al. Multiple-level lumbar total disk replacement: a prospective clinical and radiographic analysis of motion preservation at 24-72 months. Clin Spine Surg. 2019 Feb;32(1):38-42.

Rickers KW, et al. Comparison of interventions for lumbar disc herniation: a systematic review with network meta-analysis. Spine J. 2021 Oct;21(10):1750-1762.

Ries ZG, et al. Updated imaging does not affect revision rates in adults undergoing spine surgery for lumbar degenerative disease. J Neurosurg Spine. 2019;30(2):228-223.

Scott-Young M, et al. Comparison of mid-to long-term follow-up of patient-reported outcomes measures after single-level lumbar total disc arthroplasty, multi-level lumbar total disc arthroplasty, and the lumbar hybrid procedure for the treatment of degenerative disc disease. Spine. 2022 Mar 1;47(5):377-386.

Shafshak T, et al. Epidural steroid injection versus conservative measures in treatment of chronic axial low back pain, a prospective randomized controlled study. European Journal of Medical and Health Sciences. 2022;4(5):47-51.

Shafshak TS, Elnemr R. The visual analogue scale versus numerical rating scale in measuring pain severity and predicting disability in low back pain. J Clin Rheumatol. 2020;27(7):1.

Shariff S, et al. Acute back pain: the role of medication, physical medicine and rehabilitation: WFNS spine committee recommendations. World Neurosurgery. 2024 July;23:1-11.

Yue JJ and Mo FF. Clinical study to evaluate the safety and effectiveness of the Aesculap Activ-L artificial disc in the treatment of degenerative disc disease. BMC Surg. 2010 Apr 9;10:14.

Yue JJ, et al. Five-year results of a randomized controlled trial for lumbar artificial discs in single-level degenerative disc disease. Spine. (Phila Pa 1976) 2019 Dec 15;44(24):1685-1696.

Zigler JE, et al. Five-year adjacent-level degenerative changes in patients with single-level disease treated using lumbar total disc replacement with ProDisc-L versus circumferential fusion. J Neurosurg Spine. 2012 Dec;17(6):504-11.

SEARCH TERMS

Not Applicable

CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

[Lumbar Artificial Disc Replacement \(LADR\) \(NCD 150.10\)](#) [accessed 2026 Apr 29]

PRODUCT DISCLAIMER

- Services are contract dependent; if a product does not cover a service, medical policy criteria do not apply.

Medical Policy: Artificial Lumbar Intervertebral Disc

Policy Number: 7.01.63

Page: 10 of 10

- If a commercial product (including an Essential Plan or Child Health Plus product) covers a specific service, medical policy criteria apply to the benefit.
- If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.
- If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.
- If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY HISTORY/REVISION	
Committee Approval Dates	
03/18/04, 03/17/05, 01/19/06, 01/18/07, 03/20/08, 02/19/09, 01/21/10, 01/20/11, 01/19/12, 01/17/13, 01/16/14, 12/18/14, 12/17/15, 12/15/16, 12/21/17, 06/21/18, 12/20/18, 07/18/19, 01/16/20, 02/18/21, 04/15/21, 04/21/22, 05/18/23, 10/17/24, 06/26/25, 06/18/26	
Date	Summary of Changes
06/18/26	• Annual review; policy intent unchanged.
02/25/26	• Policy edit; related policy section updated.
06/26/25	• Annual review, intent to policy unchanged.
01/01/25	• Summary of changes tracking implemented.
03/18/04	• Original effective date